MNG982
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- CHOLESTEROL_HOMEOSTASIS+0.416
- TNFA_SIGNALING_VIA_NFKB+0.402
- PROTEIN_SECRETION+0.347
- HYPOXIA+0.326
- ANDROGEN_RESPONSE+0.324
- APOPTOSIS+0.296
- P53_PATHWAY+0.286
- HEME_METABOLISM+0.250
- IL6_JAK_STAT3_SIGNALING+0.244
- NOTCH_SIGNALING+0.240
Top 10 suppressed
- E2F_TARGETS-0.463
- G2M_CHECKPOINT-0.350
- OXIDATIVE_PHOSPHORYLATION-0.284
- PANCREAS_BETA_CELLS-0.249
- MYC_TARGETS_V2-0.206
- SPERMATOGENESIS-0.204
- INTERFERON_ALPHA_RESPONSE-0.137
- ALLOGRAFT_REJECTION-0.084
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.061
- KRAS_SIGNALING_DN-0.046
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG902 | — | — | 0.816 |
| 2 | MDT-AP-1369 | Med | Medulloblastoma | 0.785 |
| 3 | TCGA-CV-7411-01A-11R-2081-07 | — | — | 0.778 |
| 4 | MNG967 | — | — | 0.768 |
| 5 | MNG364 | — | — | 0.759 |
| 6 | TCGA-BA-5557-01A-01R-1514-07 | — | — | 0.759 |
| 7 | MNG1059 | — | — | 0.743 |
| 8 | SRR660895 | GTEX | — | 0.728 |
| 9 | MNG828 | — | — | 0.728 |
| 10 | SRR1388007 | GTEX | — | 0.725 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| CHOLESTEROL_HOMEOSTASIS | 0.416 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.402 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.347 | Remibrutinib | — uncovered |
| HYPOXIA | 0.326 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.324 | Inavolisib | — uncovered |
| APOPTOSIS | 0.296 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.286 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.250 | Temsirolimus | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.244 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.240 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.228 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.204 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.201 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.191 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.183 | Temsirolimus | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.180 | Inavolisib | — uncovered |
| COMPLEMENT | 0.173 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.165 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.156 | Idelalisib | — uncovered |
| COAGULATION | 0.150 | Binimetinib | — uncovered |